Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association

Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association

Safety monitoring is of paramount importance for vaccines authorized for emergent use (EUA) by the US Food and Drug Administration (FDA) against SARS-CoV-2. Mass immunization is an essential tool to end the current pandemic, but vaccine surveillance is necessary to identify any potentially associate...

Full description

Bibliographic Details
Main Authors: Osakpolor Ogbebor, Harshit Seth, Zaw Min, Nitin Bhanot
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:IDCases
Subjects:
SARS-CoV-2 vaccine
Guillain-Barré syndrome
Online Access:http://www.sciencedirect.com/science/article/pii/S2214250921000998

Similar Items

Similar Items